Albireo Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Albireo Pharma (ALBO) Tops Q2 EPS by 8c
August 8, 2019 7:38 AM EDTAlbireo Pharma (NASDAQ: ALBO) reported Q2 EPS of ($1.35), $0.08 better than the analyst estimate of ($1.43). Revenue for the quarter came in at $1.25 million versus the consensus estimate of $770 thousand.
The momentum is building for Albireo, as we advance programs on multiple fronts and ramp up... More
